Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Avrobio Inc
Healthcare
P/NCAV
0.57x
Ticker
AVRO
Exchange
NASDAQ
Country
United States
Close
1.21 $
Mkt Cap
53.9M $
EV
-44.1M $
NCAV Burn Rate
-31.6%
Current Ratio
15.78
Debt/Equity
0.0
EV/REV
N/Ax
EV/EBIT
-4.0x
EV/FCF
0.7x
Dilution
10.4% p.A
Total Net Income
-475.2M $
Cheapness
100.0%
AVROBIO, Inc. is a gene therapy company. The Company is focused on developing potentially curative hematopoietic stem cells (HSC) gene therapies to treat patients with rare diseases following a single dose treatment regimen. The gene therapies that the Company is engaged in developing employ HSCs that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The Company-s development focus has been on a group of rare genetic diseases referred to as lysosomal disorders, primarily managed with enzyme replacement therapies (ERTs). Its pipeline is comprised of three HSC gene therapy programs, which include AVR-RD-02 for the treatment of Gaucher disease type 1 and type 3; AVR-RD-03 for the treatment of Pompe disease, and AVR-RD-01 for the treatment of Fabry disease.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average